CKD Biomarkers Consortium (BioCon)


At a Glance
  • Status: Active Consortium
  • Year Launched: 2009
  • Initiating Organization: The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Initiator Type: Academia
  • Disease focus:
    Chronic Kidney Disease
  • Location: North America

Abstract

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) established the CKD Biomarkers Consortium (BioCon) to promote the discovery and validation of biomarkers to advance the field of chronic kidney disease (CKD) research. The NIDDK CKD Biomarkers Consortium brings together investigators whose expertise includes clinical nephrology, epidemiology, molecular biology, genomics, proteomics, metabolomics, systems biology, laboratory medicine, biostatistics, and laboratory test verification and qualification.

Mission

BioCon is a collaborative effort involving numerous investigators from multiple institutions working together to pursue the development and validation of novel biomarkers for CKD by assaying biological specimens and utilizing data from the nation’s largest epidemiological studies of kidney disease. Studies conducted by the CKD BioCon assay biospecimens and analyze data from various epidemiological studies of kidney disease that were previously conducted by the NIDDK, such as the AASK, MDRD, ARIC, CRIC, DCCT/EDIC cohorts, and more. Specific aims vary by study, but include identifying and evaluating biomarkers of CKD incidence, cardiovascular events, changes in kidney histology, and disease progression and outcomes. The development and validation of biomarkers that results from these studies will aid in the identification of high-risk patients and inform clinical practices for monitoring and treatment of individuals with CKD.

The CKD Biomarkers Consortium was established to pursue the discovery and validation of novel biomarkers for CKD to advance research into the causes and outcomes of the disease.

Consortium History

Phase I of BioCon began in 2009 and will continue into 2016. Phase II of BioCon began in July 2015 with a reconstituted set of investigators and scientific activities.

Financing

The phases of the program are financed via grants by the Department of Health and Human Services and other organizations

Points of Contact

Investigators interested in collaborating with the CKD Biomarkers Consortium should contact:

Krista Whitehead, MS
Research Project Manager
Perelman School of Medicine
at The University of Pennsylvania
kristaw@mail.med.upenn.edu

Sponsors & Partners

For a list of participating partners, click here


Last Updated: 06/19/2017

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.